Analysts think PMN stock price could increase by 921%
Oct 24, 2024, 11:26 AM
8.48%
What does PMN do
ProMIS Neurosciences, based in Toronto, develops precision medicine for neurodegenerative diseases, focusing on antibody therapeutics targeting misfolded proteins. The company went public on April 3, 2017, and employs six full-time staff.
2 analysts think PMN stock price will increase by 921.07%. The current median analyst target is $9.69 compared to a current stock price of $0.95. The lowest analysts target is $9.60 and the highest analyst target is $9.97.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
